IRADIMED CORPORATION IRMD
Updated: 17 Jun 2026
No signal published yet
We already track IRADIMED and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow IRADIMED CORPORATION? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow IRADIMED free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 4, 2026, IRADIMED reported Q1 2026 revenue of $22.0 million, a 13% increase year-over-year, driven by strong demand for its next-generation 3870 infusion pump. The company reaffirmed its full-year 2026 revenue guidance of $91 million to $96 million and declared a quarterly dividend of $0.20 per share. Management noted that the MRI-compatible portfolio continues to gain significant market traction.
What Firelda Watch includes for IRADIMED CORPORATION
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow IRADIMED CORPORATION? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow IRADIMED free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more